PBRM1 and nonpapillary renal cell carcinoma: Moreover, overall survival rates of patients with ccRCC, who were treated with everolimus (mTOR inhibitor), showed no significant difference based on RBFOX2 mRNA levels in the PBRM1 WT group (Fig. 6I).